Menu Back toSession-0402-Application-of-Bayesian-Methods-for-Clinical-Trials

The 7th DIA China Annual Meeting


Session 0402 Application of Bayesian Methods for Clinical Trials

Session Chair(s)

Bingming  Yi

Bingming Yi

  • Director
  • GSK, China

Maximizing Return on Investment in Designing Phase II Clinical Trials

Speaker(s)

Cong  Chen, PhD

Maximizing Return on Investment in Designing Phase II Clinical Trials

Cong Chen, PhD

  • Director
  • Merck & Co., Inc., United States
Yang  Song

A Bayesian prediction model between biomarker and clinical endpoint for dichotomous variables

Yang Song

  • Sr. Prin. Scientist, Biostatistics
  • MSD, China
Jerry  Wang

A case study for a Bayesian approach to the assessment of safety for biosimilar and its application to bridging study (CN&EN)

Jerry Wang

  • Pfizer, United States

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650